A case of recurrent bilateral uveitis independently associated with dabrafenib and pembrolizumab therapy  by Taylor, Stanford C. et al.
lable at ScienceDirect
American Journal of Ophthalmology Case Reports 2 (2016) 23e25Contents lists avaiAmerican Journal of Ophthalmology Case Reports
journal homepage: http : / /www.ajocasereports .com/Case reportA case of recurrent bilateral uveitis independently associated with
dabrafenib and pembrolizumab therapy
Stanford C. Taylor a, *, Frank Hrisomalos a, Gerald P. Linette b, P. Kumar Rao a
a Department of Ophthalmology and Visual Sciences, Washington University in St. Louis, St. Louis, MO, USA
b Division of Oncology, Washington University in St. Louis, St. Louis, MO, USAa r t i c l e i n f o
Article history:
Received 8 January 2016
Received in revised form
7 April 2016
Accepted 11 April 2016
Available online 13 April 2016
Keywords:
Dabrafenib
Pembrolizumab
Uveitis
Vasculitis* Corresponding author. Resident in Ophthalmolo
mology and Visual Sciences, Washington University in
660 South Euclid Avenue, Box 8096, Saint Louis, MO
E-mail address: TaylorS@vision.wustl.edu (S.C. Tay
http://dx.doi.org/10.1016/j.ajoc.2016.04.004
2451-9936/© 2016 The Authors. Published by Elseviera b s t r a c t
Purpose: To report the case of an adult female who presented on different occasions with recurrent
uveitis provoked by initiating therapy of two recently approved agents, dabrafenib and pembrolizumab,
for treatment of metastatic melanoma.
Observations: A 61 year old female presented with bilateral anterior uveitis after initiating therapy with
dabrafenib for advanced metastatic melanoma. Her symptoms resolved and exam improved with oral
and topical steroid therapy. Months later, she was started on pembrolizumab and transitioned off dab-
rafenib. Within days of starting pembrolizumab, she developed recurrent bilateral uveitis. This respon-
ded to escalating doses of topical and oral corticosteroid therapy and resolved following discontinuation
of pembrolizumab. Nine months later, our patient received her third dose of pembrolizumab due to
further progression of melanoma and within three days developed blurry vision, photophobia and
subsequent ophthalmologic exam demonstrated bilateral panuveitis.
Conclusions and importance: Dabrafenib and pembrolizumab therapy have both previously been asso-
ciated with uveitis. Here, we document a case of a woman who developed acute uveitis in response to
beginning therapy with dabrafenib and then later developed acute uveitis soon after initiating pem-
brolizumab. To our knowledge, this is the ﬁrst time this uncommon side-effect has been reported in the
same patient after receiving sequential targeted agents and checkpoint inhibitors.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The treatment of metastatic cutaneous melanoma has tradi-
tionally been challenging and often associated with a poor prog-
nosis [1]. However, over the past ﬁve years multiple agents have
been developed that show promise in successfully treating this
aggressive neoplasm. One of these medications, dabrafenib
(Taﬁnlar™; Novartis, Basel, Switzerland), is a reversible adenosine
triphosphate-competitive inhibitor that selectively blocks BRAF
kinase, resulting in inhibition of the MAPK pathway in melanoma
cells [2]. Another novel drug used for treatment of advanced mel-
anoma is pembrolizumab (Keytruda™; Merck, Kenilworth, New
Jersey, USA), a monoclonal antibody against the T-cell co-inhibitory
receptor programmed death (PD-1) protein. While dabrafenibgy, Department of Ophthal-
St. Louis, McMillan Building,
63110, USA.
lor).
Inc. This is an open access article udecreases cancer cell proliferation by inhibiting the oncogene
BRAFV600E within tumor cells [2], pembrolizumab functions by
increasing the immune systems T-cell response to tumor antigens
[3]. Side-effects are pervasive with both therapies and thought to
occur in approximately 40e50% of patients [3e5]. Eye speciﬁc
complications of therapy, however, are infrequent and rarely re-
ported in the literature. Although ocular effects are uncommon and
despite the differences in theirmechanism of action, herewe report
a case of a 61 year old female who developed bilateral uveitis
shortly after initiating therapy with dabrafenib and then later
developed this same reaction when given pembrolizumab. The
patient provided written consent for publication of personal in-
formation including medical record details and photographs.
2. Case report
A 61 year old Caucasian female undergoing treatment for met-
astatic melanoma was initially referred to our eye clinic in 2013 for
an ocular screening exam prior to beginning an experimental
therapy. She was originally diagnosed with stage I malignantnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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shave biopsy in May 2007. Subsequent wide local excision failed to
eliminate the tumor and in October 2007, positron emission to-
mography (PET) scan demonstrated a possible mass lesion in the
right upper lung. Unfortunately, the patient was lost to follow-up
until November 2012 when she developed fatigue and weight
loss. Repeat imaging in April 2013 showed lesions concerning for
metastases to the inguinal, axillary, and pectoralis regions. Axillary
biopsy at that time conﬁrmed metastatic melanoma and her tumor
tested BRAFV600E positive by Cobas 4800 assay (Roche Molecular
Diagnostics).
Over the next several months, she was enrolled in a randomized
controlled trial with a combination therapy of vemurafenib (Zel-
boraf™; Roche, Basel, Switzerland) and cobimetinib (Cotellic™;
Roche, Basel, Switzerland) or placebo. Her eye exam at that time
was unremarkable and she denied a prior history of uveitis. Due to
drug-induced liver injury her therapy was discontinued August
2013 but staging computed tomography (CT) scans demonstrated
reduction in overall tumor burden. When CT scans in January 2014
off therapy demonstrated tumor progression with worsening
axillary and sub-pectoral adenopathy, the patient began commer-
cial dabrafenib/trametinib (Mekinist™; GlaxoSmithKline, Research
Triangle Park, North Carolina, USA) combination therapy. Within a
month, she again developed a drug-induced liver injury and so this
therapy was discontinued and ipilimumab (Yervoy™; Bristol-
Myers Squibb, New York, New York, USA) was initiated in May
2014. Despite four doses of ipilimumab, imaging in August 2014
showed metastatic progression and brain magnetic resonance im-
aging (MRI) showed interval development of multiple punctate
intracranial metastases. Ipilimumab was discontinued and she was
restarted on single agent dabrafenib.
Within days of beginning dabrafenib therapy, the patient pre-
sented to our clinic in September 2014with a sensation of ﬂashes of
light and ﬂoaters in the left greater than right eye. Examination
revealed a hemorrhagic posterior vitreous detachment of the left
eye but no cell or ﬂarewas noted. Twoweeks later, shewas noted to
have 1 þ cell by standardized criteria [6] in the left anterior
chamber and few keratic precipitates on the corneal endothelium
and she was started on topical prednisolone acetate four times
daily to the left eye. At her subsequent follow-up appointment
October 2014, slit-lamp exam demonstrated vitreous debris and
trace cell in both eyes along with a single keratic precipitate in the
right eye and so prednisolone acetate was added to the right eye
four times daily. Given the bilateral nature of her uveitis, systemic
evaluation for an underlying etiology was pursued and showed a
negative RPR, FTA-ABS, HLA-B27, and QuantiFERON-Tb Gold. Her
ACEwas elevated to 105 but this was determined to be secondary to
the effect of immunomodulatory therapy as opposed to underlying
sarcoidosis. Throughout this period, our patient's vision was never
worse than 20/40 in either eye and she was maintained on dab-
rafenib therapy at the approved dose of 150 mg by mouth twice
daily. In November 2014, she had obtained complete resolution of
symptoms, her visual acuity was back at its baseline, and she had no
evidence of active inﬂammation in the eye. Her prednisolone ace-
tate was tapered to twice daily in both eyes. Repeat MRI of the brain
in November 2014 also showed resolution of the previously noted
punctate intracranial metastases.
On 12/16/2014, our patient started therapywith pembrolizumab
and dabrafenib was stopped at the beginning of January 2015.
Within three days of starting pembrolizumab, she noted decreased
vision in both eyes accompanied by ﬂoaters and ﬂashes of light.
Visual acuity at her subsequent appointment in January 2015 was
noted to be 20/70 and 20/125 in the right and left eyes, respectively.
She was further noted to have 1e2þ vitreous cell as well as small
keratic precipitates in both eyes. Topical prednisolone acetate wasincreased to four times daily and two weeks later she had symp-
tomatic and clinical improvement. She continued cancer therapy
and was given her second dose of pembrolizumab on 1/28/2015. At
a follow-up appointment two weeks later she was noted to have
worsening vitreous cell. Prednisone 40 mg oral daily was added to
treat her uveitis as well as for the concern of a developing grade
two autoimmune colitis. Her topical and oral prednisone were
successfully tapered and by May 2015 she was off all steroids, her
examwas negative for signs of recurrent uveitis, and her vision had
returned to 20/25 and 20/30 in the right and left eyes, respectively.
Follow-up brain MRI showed no evidence of recurrence of intra-
cranial metastases and her sub-pectoral adenopathy had resolved.
Consequently, the decision was made to continue monitoring the
patient without giving additional anti-tumorigenic agents.
In November 2015, surveillance CT showed progression of dis-
ease and pembrolizumab monotherapy was re-initiated. In an
effort to prevent recurrent uveitis our patient was also started on a
prophylactic dose of topical prednisolone acetate four times daily to
both eyes. Within days of starting therapy, though, she developed
ﬂashes of light and ﬂoaters in her vision and when evaluated in
clinic was noted to have 20/80 and 20/250 vision in the right and
left eyes, respectively. Exam demonstrated 1 þ anterior chamber
cell and 2 þ vitreous cell in both eyes. Fluorescein angiography
obtained at this appointment also showed retinal vasculitis in both
eyes (Fig. 1). Given her presentation with panuveitis, treatment
with prednisone 40 mg oral daily was once again initiated. At a
follow-up appointment two weeks later, her vision had improved
to 20/50 in both eyes, the anterior chamber reaction resolved, but
she still had persistent vitreous inﬂammation and retinal vasculitis.
A decision was made to continue with pembrolizumab therapy as
long as her uveitis could be managed with corticosteroid therapy.
3. Discussion
Ocular complications of dabrafenib and pembrolizumab therapy
are uncommon. Dry eye syndrome, endophthalmitis, uveitis, optic
neuritis, and papillitis have all been previously reported with
pembrolizumab [3,4,7]. In patients taking dabrafenib in combina-
tion with trametinib, chorioretinopathy and uveitis infrequently
occur [5,8e10]. To our knowledge, here we present the ﬁrst case of
a patient who developed uveitis as a response to initiating both
dabrafenib and, later, pembrolizumab. The temporal relationship
between chemotherapy initiation and uveitis onset strongly sug-
gests medication induced uveitis as the cause of her ﬁndings.
However, it should be noted both of these anti-tumorigenic med-
ications have different mechanisms of action. Dabrafenib exerts its
effect on cancer cells as an oral serine kinase inhibitor. In contrast,
pembrolizumab, an immune checkpoint blocking antibody, in-
creases the immune response to metaplasia. Furthermore, pem-
brolizumab is a humanized IgG4 antibody while dabrafenib is a
methanesulfonate salt. Despite these differences, our patient un-
fortunately had the propensity of developing acute uveitis soon
after initiating therapy with these agents on multiple occasions.
Other potential etiologies to our patient's presentation were
also considered. She had no prior history of inﬂammatory disease
and a normal screening eye exam prior to initiating chemotherapy.
Serologic work-up failed to demonstrate an infectious etiology such
as tuberculosis or syphilis. Furthermore, her presentation was not
thought to represent drug-induced sarcoidosis as she didn't have
accompanying systemic ﬁndings of sarcoidosis. A case of metastatic
melanoma to the vitreous has also previously been reported in a
patient taking pembrolizumab [11], but we did not think this likely
in our patient as she presentedwith bilateral ﬁndings and her exam
normalized with corticosteroids and cessation of cancer therapy.
Another possibility is that the uveitis was secondary to an immune
Fig. 1. Fluorescein angiogram of both eyes, taken two weeks after re-starting pembrolizumab therapy, with serial images capturing contrast transit through the left eye. A) Early
laminar venous phase of the left eye. B) Late phase angiogram of the left eye showing diffuse vasculitis and RPE disturbance. C) Late phase angiogram of the right eye showing
diffuse vasculitis and RPE disturbance.
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therapy.
While unable to deﬁnitely prove the cause of our patient's
uveitis, the temporal relationship of chemotherapy initiation and
onset of eye symptoms on three different occasions strongly sug-
gest an inﬂammatory effect of pembrolizumab and dabrafenib on
the eyes. Ongoing safety surveillance of these medications will
better elucidate the frequency of uveitis in pembrolizumab and
dabrafenib and also clarify the potential link between
pembrolizumab-associated and dabrafenib-associated uveitis.
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